Faulty chromatin remodeling may contribute to development of ovarian clear cell carcinoma

-- Monica Smith

Monday, September 13, 2010 (Last Updated: 09/14/2010)

MONDAY, Sept. 13 (HealthDay News) -- Ovarian clear cell carcinoma (OCCC), a particularly aggressive form of ovarian cancer often resistant to standard therapy, appears to be associated with mutations of two specific genes, according to research published online Sept. 8 in Science.

Sian Jones, Ph.D., of the Johns Hopkins Kimmel Cancer Center in Baltimore, and colleagues analyzed genes in ovarian clear cell tumors from eight patients and in normal cells from the same patients to determine the genetic origin of OCCC.

The researchers found 268 mutations in 253 genes from the eight tumors, averaging 20 mutations per tumor. In an additional 34 OCCC patients, mutations of ARID1A genes, which normally suppress tumors, were found in more than half (57 percent) of 42 OCCCs, and mutations of PPP2R1A genes were found in 7.1 percent. Neither gene has previously been linked to ovarian cancer.

"These results suggest that aberrant chromatin remodeling contributes to the pathogenesis of OCCC," the authors write.

Full Text (subscription or payment may be required)

Specialties Hematology & Oncology
Internal Medicine
Family Practice

Copyright © 2010 HealthDay. All rights reserved.


Be Kind
by OncoLink Editorial Team
January 26, 2015

7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015